Konstas, Anastasios G Schmetterer, Leopold Katsanos, Andreas Hutnik, Cindy M L Holló, Gábor Quaranta, Luciano Teus, Miguel A Uusitalo, Hannu Pfeiffer, Norbert Katz, L Jay
...
Published in
Advances in therapy
The key clinical attributes of preserved dorzolamide/timolol fixed combination (DTFC) and the emerging potential of preservative-free (PF) DTFC are reviewed with published evidence and clinical experience. The indications and role of DTFC in current glaucoma management are critically discussed. Preserved DTFC became the first intraocular pressure (...
Thangavel, Rajeswari Surve, Abhidnya Azad, Shorya Kumar, Vinod
Published in
Indian Journal of Ophthalmology
Macular involvement is commonly seen in cases with X-linked retinoschisis (XLRS) which includes foveal schisis and cystic maculopathy. Although no definitive treatment has been described, the use of topical 2% dorzolamide hydrochloride in such cases has shown varied response. We herein report a case of XLRS with foveal schisis showing good response...
Strauß, Olaf
Published in
Karger Kompass Ophthalmologie
Background: Diabetic retinopathy is characterised by morphological lesions in the retina secondary to disturbances in retinal blood flow. Previous studies have shown that the carbonic anhydrase inhibitor (CAI) dorzolamide can induce immediate dilatation of retinal arterioles and a sustained increase in retinal blood flow in primary open-angle glauc...
Tilma, Kathrine Kleis Bek, Toke
Published in
Ophthalmologica
Background: Diabetic retinopathy is characterised by morphological lesions in the retina secondary to disturbances in retinal blood flow. Previous studies have shown that the carbonic anhydrase inhibitor (CAI) dorzolamide can induce immediate dilatation of retinal arterioles and a sustained increase in retinal blood flow in primary open-angle glauc...
Mirshahi, Ahmad Tadayoni, Ramin Mohsenzadeh, Navid Saeidi Rezvani, Talieh Abrishami, Mojtaba
Published in
Journal of Current Ophthalmology
Purpose To assess the efficacy of adjuvant topical timolol–dorzolamide with intravitreal bevacizumab (IVB) injection on anatomic and functional results in eyes affected with diabetic macular edema (DME). Methods In an interventional prospective contralateral pilot eye study at a third level referral academic facility, patients with bilateral DME wh...
CHRISTODOULOU, Panayiotis TANTELES, George NIKOLAOU, Nayia KATSIMBRIS, Ioannis STEFANIOTOU, Maria
Published in
Medical Hypothesis, Discovery and Innovation in Ophthalmology
To investigate how genotype is related to phenotype and document correlations of genotype-phenotype with response of topical administration of dorzolamide in siblings affected with X-linked juvenile retinoschisis (XLRS). We performed a retrospective study on two male siblings (four eyes) with XLRS, who were treated with topical installation of dorz...
Shah, Tirth J. Moshirfar, Majid Hoopes, Phillip C. Sr
Published in
Ophthalmology and Therapy
Our purpose is to present an evidence-based approach, directed primarily towards eye-care specialists, clarifying whether certain drugs should or should not be used in patients with sulfonamide allergy. We conducted a literature search using PubMed to identify the risk of ophthalmic-specific drugs in patients with a self-reported sulfonamide allerg...
Park, Chun Gwon Kim, Young Kook Kim, Se-Na Lee, Seung Ho Huh, Beom Kang Park, Min-A Won, Hyein Park, Ki Ho Choy, Young Bin
Published in
International journal of pharmaceutics
Dorzolamide eye drops are widely prescribed to reduce intraocular pressure (IOP) in the treatment of ocular hypertension and glaucoma. However, in an eye drop formulation, dorzolamide is rapidly cleared from the preocular space, hence requiring multiple daily administrations. Here, we sought to increase the preocular retention of dorzolamide using ...
Manchanda, Satish Sahoo, Pravat K.
Published in
Journal of Pharmaceutical Investigation
The purpose of this study was to prepare chitosan-dextran sulphate and chitosan-sodium tripolyphosphate nanoparticles of Dorzolamide HCl. Dorzolamide HCl is used in higher doses (2–2.2%) topically resulting topical as well as systemic side effects, reducing the dose and making the formulation stay in ocular cavity can reduce the side effects. In th...
Quaranta, L Biagioli, E Galli, F Poli, D Rulli, E Riva, I Hollander, L Katsanos, A Longo, A Uva, MG
...